Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on the results of a post hoc analysis of a large clinical trial database comparing the safety profiles of zanubrutinib and ibrutinib in patients with B-cell malignancies. It was shown that zanubrutinib was associated with a lower rate of serious adverse events, cardiac events, and treatment discontinuation. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть